<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Bone HK</submitter><funding>Medical Research Council</funding><funding>Wellcome Trust</funding><funding>Engineering and Physical Sciences Research Council</funding><pagination>1992-2000</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3104033</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>124(Pt 12)</volume><pubmed_abstract>The use of small molecules to 'chemically direct' differentiation represents a powerful approach to promote specification of embryonic stem cells (ESCs) towards particular functional cell types for use in regenerative medicine and pharmaceutical applications. Here, we demonstrate a novel route for chemically directed differentiation of human ESCs (hESCs) into definitive endoderm (DE) exploiting a selective small-molecule inhibitor of glycogen synthase kinase 3 (GSK-3). This GSK-3 inhibitor, termed 1m, when used as the only supplement to a chemically defined feeder-free culture system, effectively promoted differentiation of ESC lines towards primitive streak (PS), mesoderm and DE. This contrasts with the role of GSK-3 in murine ESCs, where GSK-3 inhibition promotes pluripotency. Interestingly, 1m-mediated induction of differentiation involved transient NODAL expression and Nodal signalling. Prolonged treatment of hESCs with 1m resulted in the generation of a population of cells displaying hepatoblast characteristics, that is expressing α-fetoprotein and HNF4α. Furthermore, 1m-induced DE had the capacity to mature and generate hepatocyte-like cells capable of producing albumin. These findings describe, for the first time, the utility of GSK-3 inhibition, in a chemically directed approach, to a method of DE generation that is robust, potentially scalable and applicable to different hESC lines.</pubmed_abstract><journal>Journal of cell science</journal><pubmed_title>A novel chemically directed route for the generation of definitive endoderm from human embryonic stem cells based on inhibition of GSK-3.</pubmed_title><pmcid>PMC3104033</pmcid><funding_grant_id>GR/S99419/01</funding_grant_id><funding_grant_id>MC_G1000732</funding_grant_id><pubmed_authors>Nelson AS</pubmed_authors><pubmed_authors>Goldring CE</pubmed_authors><pubmed_authors>Tosh D</pubmed_authors><pubmed_authors>Welham MJ</pubmed_authors><pubmed_authors>Bone HK</pubmed_authors></additional><is_claimable>false</is_claimable><name>A novel chemically directed route for the generation of definitive endoderm from human embryonic stem cells based on inhibition of GSK-3.</name><description>The use of small molecules to 'chemically direct' differentiation represents a powerful approach to promote specification of embryonic stem cells (ESCs) towards particular functional cell types for use in regenerative medicine and pharmaceutical applications. Here, we demonstrate a novel route for chemically directed differentiation of human ESCs (hESCs) into definitive endoderm (DE) exploiting a selective small-molecule inhibitor of glycogen synthase kinase 3 (GSK-3). This GSK-3 inhibitor, termed 1m, when used as the only supplement to a chemically defined feeder-free culture system, effectively promoted differentiation of ESC lines towards primitive streak (PS), mesoderm and DE. This contrasts with the role of GSK-3 in murine ESCs, where GSK-3 inhibition promotes pluripotency. Interestingly, 1m-mediated induction of differentiation involved transient NODAL expression and Nodal signalling. Prolonged treatment of hESCs with 1m resulted in the generation of a population of cells displaying hepatoblast characteristics, that is expressing α-fetoprotein and HNF4α. Furthermore, 1m-induced DE had the capacity to mature and generate hepatocyte-like cells capable of producing albumin. These findings describe, for the first time, the utility of GSK-3 inhibition, in a chemically directed approach, to a method of DE generation that is robust, potentially scalable and applicable to different hESC lines.</description><dates><release>2011-01-01T00:00:00Z</release><publication>2011 Jun</publication><modification>2025-04-22T08:48:10.902Z</modification><creation>2019-03-27T00:42:06Z</creation></dates><accession>S-EPMC3104033</accession><cross_references><pubmed>21610099</pubmed><doi>10.1242/jcs.081679</doi></cross_references></HashMap>